Outcomes of 35 dogs with craniomaxillofacial osteosarcoma treated with stereotactic body radiation therapy.
canine
craniomaxillofacial
osteosarcoma
radiotherapy
stereotactic
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
21 Jan 2024
21 Jan 2024
Historique:
revised:
19
12
2023
received:
17
07
2023
accepted:
21
12
2023
medline:
22
1
2024
pubmed:
22
1
2024
entrez:
21
1
2024
Statut:
aheadofprint
Résumé
Canine craniomaxillofacial osteosarcoma (OSA) is most commonly treated surgically; however, in cases where surgery is not feasible or non-invasive treatment is desired, stereotactic body radiation therapy (SBRT) may be elected for local tumour control. In this study, we evaluated 35 dogs treated with SBRT. Nine dogs (26%) had calvarial, seven (20%) had mandibular and 19 (54%) had maxillary OSA. Median time to first event (TFE) was 171 days, and overall median survival time (MST) was 232 days. Site-specific MSTs were 144 days for mandible, 236 days for calvarium and 232 days for maxilla (p = .49). Pulmonary metastatic disease was observed in 12/35 (34%) patients and was detected pre-SBRT in six dogs (17%) and post-SBRT in the remaining six dogs (17%). Eighteen adverse events post-SBRT were documented. Per veterinary radiation therapy oncology group criteria, five were acute (14%) and three were late (9%) grade 3 events. Neurological signs in two dogs were suspected to be early-delayed effects. Cause of death was local progression for 22/35 (63%) patients, metastasis for 9/35 (26%) patients and unknown for four. On univariate analysis, administration of chemotherapy was associated with a longer TFE (p = .0163), whereas volume of gross tumour volume was associated with a shorter TFE (p = .023). Administration of chemotherapy and five fractions versus single fraction of SBRT was associated with increased survival time (p = .0021 and .049). Based on these findings, a treatment protocol incorporating chemotherapy and five fractions of SBRT could be considered for dogs with craniomaxillofacial OSA electing SBRT with careful consideration of normal tissues in the field.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Mason NJ. Comparative immunology and immunotherapy of canine osteosarcoma. In: Kleinerman ES, Gorlick R, eds. Current Advances in the Science of Osteosarcoma: Research Perspectives: Tumor Biology, Organ Microenvironment, Potential New Therapeutic Targets, and Canine Models. Springer International Publishing; 2020:199-221.
Heyman SJ, Diefenderfer DL, Goldschmidt MH, Newton CD. Canine axial skeletal osteosarcoma. A retrospective study of 116 cases (1986 to 1989). Vet Surg. 1992;21(4):304-310.
Thompson KG, Pool RR. InIn: Meuten DJ, ed. Tumors in Domestic Animals. 2nd ed. Iowa State Press; 2002:263-283.
Schwarz PD, Withrow SJ, Curtis CR, Powers BE, Straw RC. Mandibular resection as a treatment for oral cancer in 81 dogs. J Am Anim Hosp Assoc. 1991;27:601-610.
Schwarz PD, Withrow SJ, Curtis CR, Powers BE, Straw RC. Partial maxillary resection as a treatment for oral cancer in 61 dogs. J Am Anim Hosp Assoc. 1991;27:617-624.
Selmic LE, Lafferty MH, Kamstock DA, et al. Outcome and prognostic factors for osteosarcoma of the maxilla, mandible, or calvarium in dogs: 183 cases (1986-2012). J Am Vet Med Assoc. 2014;245(8):930-938.
Coyle VJ, Rassnick KM, Borst LB, et al. Biological behaviour of canine mandibular osteosarcoma. A retrospective study of 50 cases (1999-2007): canine mandibular osteosarcoma. Vet Comp Oncol. 2015;13(2):89-97.
Farcas N, Arzi B, Verstraete FJM. Oral and maxillofacial osteosarcoma in dogs: a review: canine oral osteosarcoma. Vet Comp Oncol. 2014;12(3):169-180.
Hammer AS, Weeren FR, Weisbrode SE, Padgett SL. Prognostic factors in dogs with osteosarcomas of the flat or irregular bones. J Am Anim Hosp Assoc. 1995;31(4):321-326.
Straw RC, Powers BE, Klausner J, et al. Canine mandibular osteosarcoma: 51 cases (1980-1992). J Am Anim Hosp Assoc. 1996;32(3):257-262.
Gardner HL, Sivaprakasam K, Briones N, et al. Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. Commun Biol. 2019;2(1):1-13. doi:10.1038/s42003-019-0487-2
Hosoya K, Poulson JM, Azuma C. Osteoradionecrosis and radiation induced bone tumors following orthovoltage radiation therapy in dogs. Vet Radiol Ultrasound. 2008;49(2):189-195.
Thrall DE, Goldschmidt MH, Biery DN. Malignant tumor formation at the site of previously irradiated acanthomatous epulides in four dogs. J Am Vet Med Assoc. 1981;178(2):127-132.
White RA, Jefferies AR, Gorman NT. Sarcoma development following irradiation of acanthomatous epulis in two dogs. Vet Rec. 1986;118(24):668.
Ehrhart NP, Christensen NI, Fan TM. Tumors of the skeletal system. In. In: Vail DM, Thamm DH, Liptak JS, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier; 2020:524-564.
Farese JP, Milner R, Thompson MS, et al. Stereotactic radiosurgery for treatment of osteosarcomas involving the distal portions of the limbs in dogs. J Am Vet Med Assoc. 2004;225(10):1567-1572.
Ladue T, Klein MK. Toxicity criteria of the veterinary radiation therapy oncology group. Vet Radiol Ultrasound. 2001;42(5):475-476.
Harmon J, Van Ufflen D, Larue S. Assessment of a radiotherapy patient cranial immobilization device using daily on-board kilovoltage imaging. Vet Radiol Ultrasound. 2009;50(2):230-234.
Rohrer Bley C, Meier VS, Besserer J, Schneider U. Intensity-modulated radiation therapy dose prescription and reporting: sum and substance of the international commission on radiation units and measurements report 83 for veterinary medicine. Vet Radiol Ultrasound. 2019;60(3):255-264.
Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg. 2000;93(Suppl 3):219-222.
Kataria T, Sharma K, Subramani V, Karrthick KP, Bisht SS. Homogeneity index: an objective tool for assessment of conformal radiation treatments. J Med Phys. 2012;37(4):207-213.
Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a veterinary cooperative oncology group (VCOG) consensus document. Vet. comp. Oncol. 2015;13(3):176-183.
Dickerson ME, Page RL, LaDue TA, et al. Retrospective analysis of axial skeleton osteosarcoma in 22 large-breed dogs. J Vet Int Med. 2001;15(2):120-124.
Kosovsky JK, Matthiesen DT, Marretta SM, Patnaik AK. Results of partial mandibulectomy for the treatment of oral tumors in 142 dogs. Vet Surg. 1991;20(6):397-401.
Tofilon PJ, Fike JR. The radioresponse of the central nervous system: a dynamic process. Radiat Res. 2000;153(4):357-370.
Turnquist C, Harris BT, Harris CC. Radiation-induced brain injury: current concepts and therapeutic strategies targeting neuroinflammation. Neurooncol Adv. 2020;2(1):1-10.
Reczynska AI, LaRue SM, Boss MK, et al. Outcome of stereotactic body radiation for treatment of nasal and nasopharyngeal lymphoma in 32 cats. J Vet Intern Med. 2022;36(2):733-742.
Lee BI, LaRue SM, Seguin B, et al. Safety and efficacy of stereotactic body radiation therapy (SBRT) for the treatment of canine thyroid carcinoma. Vet Comp Oncol. 2020;18(4):843-853.
Martin TW, LaRue SM, Griffin L, Leary D, Boss MK. Retrospective study evaluating the efficacy of stereotactic body radiation therapy for the treatment of confirmed or suspected primary pulmonary carcinomas in dogs. Vet Comp Oncol. 2023;21(4):656-664.
Gieger TL, Nolan MW. Linac-based stereotactic radiation therapy for canine non-lymphomatous nasal tumours: 29 cases (2013-2016). Vet Comp Oncol. 2018;16(1):68-75.